Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
- PMID: 476006
- DOI: 10.1111/j.1365-2141.1979.tb01167.x
Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
Abstract
Plasma concentrations of desferrioxamine and ferrioxamine were measured following bolus injections of desferrioxamine and during 24 h infusions of the drug. [59Fe]ferrioxamine clearance and urinary iron excretion were also measured. Higher plasma ferrioxamine concentrations were found in iron loaded subjects and higher desferrioxamine concentrations in subjects with normal ironloads. There is a correlation between the circulating concentration of ferrioxamine during an infusion and the 48 h urinary iron excretion. The data suggests that the amount of iron chelated in vivo is related to an increase in the size of an intermediate chelatable pool rather than the total amount of the iron load. The well-recognized delay in urinary iron excretion appears to be related to active tubular reabsorption of ferrioxamine.
Similar articles
-
Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.Biochem J. 1988 Sep 15;254(3):869-75. doi: 10.1042/bj2540869. Biochem J. 1988. PMID: 3196300 Free PMC article.
-
Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.Eur J Pediatr. 1989 Apr;148(6):503-6. doi: 10.1007/BF00441542. Eur J Pediatr. 1989. PMID: 2744011
-
Characterization of siderophore-mediated iron transport in Geotrichum candidum, a non-siderophore producer.Biol Met. 1990;2(4):209-13. doi: 10.1007/BF01141361. Biol Met. 1990. PMID: 2143917
-
Deferoxamine pharmacokinetics.Semin Hematol. 2001 Jan;38(1 Suppl 1):63-8. doi: 10.1016/s0037-1963(01)90061-7. Semin Hematol. 2001. PMID: 11206963 Review.
-
Oral iron chelators: prospects for future development.Eur J Haematol. 1989 Oct;43(4):271-85. doi: 10.1111/j.1600-0609.1989.tb00300.x. Eur J Haematol. 1989. PMID: 2684681 Review. No abstract available.
Cited by
-
Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.J Exp Med. 1984 Nov 1;160(5):1532-43. doi: 10.1084/jem.160.5.1532. J Exp Med. 1984. PMID: 6333485 Free PMC article.
-
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.Antimicrob Agents Chemother. 1990 Sep;34(9):1833-5. doi: 10.1128/AAC.34.9.1833. Antimicrob Agents Chemother. 1990. PMID: 2285303 Free PMC article.
-
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.Antimicrob Agents Chemother. 1995 Sep;39(9):2023-6. doi: 10.1128/AAC.39.9.2023. Antimicrob Agents Chemother. 1995. PMID: 8540710 Free PMC article.
-
Iron chelators as therapeutic agents against Pneumocystis carinii.Antimicrob Agents Chemother. 1994 May;38(5):997-1003. doi: 10.1128/AAC.38.5.997. Antimicrob Agents Chemother. 1994. PMID: 8067783 Free PMC article.
-
Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial.Antioxidants (Basel). 2021 Aug 10;10(8):1270. doi: 10.3390/antiox10081270. Antioxidants (Basel). 2021. PMID: 34439518 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical